Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - BIOCRYST PHARMACEUTICALS INC | g27098exv99w1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): May 4, 2011
BioCryst Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
| Delaware (State or other jurisdiction of incorporation) |
000-23186 (Commission File Number) |
62-1413174 (IRS Employer Identification No.) |
4505 Emperor Blvd., Suite 200, Durham, North Carolina 27703
(Address of Principal Executive Offices) (Zip Code)
(Address of Principal Executive Offices) (Zip Code)
(Registrant’s telephone number, including area code): (919) 859-1302
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
o
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 2.02 | Results of Operations and Financial Condition. |
On May 4, 2011, BioCryst Pharmaceuticals, Inc. (the “Company”) issued a news release announcing
recent corporate developments and its financial results for the quarter ended March 31, 2011, which
also referenced a conference call to discuss these recent corporate developments and financial
results. A copy of the news release is furnished as Exhibit 99.1 hereto and is incorporated herein
by reference.
| Item 7.01 | Regulation FD Disclosure |
The information furnished on Exhibit 99.1 is incorporated by reference under this Item 7.01 as if
fully set forth herein.
The information furnished is not deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, is not subject to the liabilities of that section and is not
deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
| Exhibit No. |
Description | |
99.1
|
Press release dated May 4, 2011 entitled “BioCryst Provides Corporate Update and Reports First Quarter 2011 Financial Results” |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| BioCryst Pharmaceuticals, Inc. |
||||
| By: | /s/ Alane Barnes | |||
| Name: | Alane Barnes | |||
| Title: | Vice President, General Counsel and Corporate Secretary |
|||
Date: May 4, 2011
3
INDEX TO EXHIBITS
| Exhibit No. |
Description | |
99.1
|
Press release dated May 4, 2011 entitled “BioCryst Provides Corporate Update and Reports First Quarter 2011 Financial Results” |
4